

The logo for PHARMAC (Te Pātaka Whaioranga) is a white circle containing the text 'PHARMAC' in a large, bold, sans-serif font, with 'TE PĀTAKA WHAIORANGA' in a smaller, all-caps, sans-serif font below it. The background of the entire page is a grey-to-white gradient with a large, intricate, white geometric pattern of concentric, overlapping lines that form a complex, maze-like or cellular structure.

PHARMAC
TE PĀTAKA WHAIORANGA

Pharmaceutical Management Agency
New Zealand
Pharmaceutical Schedule

Update

April 2022

Contents

Summary of Pharmac decisions effective 1 April 2022	3
Tender News	5
Looking Forward	5
Sole Subsidised Supply (SSS) or Principal Supply Status (PSS) Products – Cumulative to April 2022.....	6
New Listings.....	22
Changes to Restrictions, Chemical Names and Presentations	23
Changes to Subsidy and Manufacturer’s Price.....	29
Delisted Items	30
Items to be Delisted	31
Index.....	33

Summary of Pharmac decisions

EFFECTIVE 1 APRIL 2022

New listings (page 22)

- Oil in water emulsion (Fatty Cream AFT) crm, 500 g
- Pharmacy services (BSF Vigisom) brand switch fee (Pharmacode 2634112) – may only be claimed once per patient
- Pharmacy services (BSF Cinacalcet Devatis) brand switch fee (Pharmacode 2634120) – may only be claimed once per patient
- Pharmacy services (BSF Comtan) brand switch fee (Pharmacode 2634139) – may only be claimed once per patient
- Amino acid formula (Alfamino) powder, 400 g OP (Pharmacode 2632187) – Special Authority – Hospital Pharmacy [HP3]
- Amino acid formula (Alfamino Junior) powder, 400 g OP (Pharmacode 2634848) – Special Authority – Hospital Pharmacy [HP3]

Changes to restrictions (pages 23-28)

- Cinacalcet (Cinacalcet Devatis) tab 30 mg – addition of brand switch fee payable
- Zoledronic acid (Zoledronic acid Mylan) inj 4 mg per 5 ml, vial – amended Special Authority criteria
- Zoledronic acid (Aclasta) inj 0.05 mg per ml, 100 ml, vial, 100 ml OP – amended Special Authority criteria
- Febuxostat (Febuxostat multichem) tab 80 mg and 120 mg – removal of brand switch fee payable
- Entacapone (Comtan) tab 200 mg – addition of brand switch fee payable
- Pregabalin cap 150 mg (Lyrica and Pregabalin Pfizer) and cap 300 mg (Pregabalin Pfizer) – removal of stat
- Melatonin (Vigisom) tab modified-release 2 mg – addition of brand switch fee payable
- Erlotinib (Tarceva) tab 100 mg and 150 mg – amended Special Authority criteria
- Gefitinib (Iressa) tab 250 mg – amended Special Authority criteria
- Sunitinib (Sunitinib Pfizer and Sutent) cap 12.5 mg, 25 mg and 50 mg – amended Special Authority criteria
- Abiraterone acetate (Zytiga) tab 250 mg – amended Special Authority criteria
- Octreotide long-acting (Octreotide Depot Teva) inj depot 10 mg, 20 mg and 30 mg prefilled syringe – amended Special Authority criteria
- Rituximab (Riximyo) inj 100 mg per 10 ml vial, inj 500 mg per 50 ml vial (Riximyo) and inj 1 mg for ECP (Baxter (Riximyo)) – amended Special Authority criteria

Summary of Pharmac decisions – effective 1 April 2022 (continued)

- Nivolumab inj 10 mg per ml, 4 ml and 10 ml vial (Opdivo) and inj 1 mg for ECP (Baxter) – amended Special Authority criteria
- Pembrolizumab inj 25 mg per ml, 4 ml vial (Keytruda) and inj 1 mg for ECP (Baxter) – amended Special Authority criteria

Increased subsidy (page 29)

- Salmeterol aerosol inhaler CFC-free, 25 mcg per dose, 120 dose OP (Serevent) and powder for inhalation, 50 mcg per dose, breath activated, 60 dose OP (Serevent Accuhaler)

Decreased subsidy (page 29)

- Spironolactone (Spiractin) tab 25 mg and 100 mg
- Aqueous cream (Boucher) crm, 500 g
- Carbimazole (Neo-Mercazole) tab 5 mg
- Colchicine (Colgout) tab 500 mcg
- Carmustine inj 100 mg vial (BiCNU) and inj 1 mg for ECP (Baxter)
- Promethazine hydrochloride (Allersoothe) tab 10 mg and 25 mg

Tender News

Sole Subsidised Supply (SSS) or Principal Supply Status (PSS) changes – effective 1 May 2022

Chemical Name	Presentation; Pack size	PSS/ SSS	PSS/SSS brand (and supplier)
Buspirone hydrochloride	Tab 5 mg; 100 tab Tab 10 mg; 100 tab	PSS	Buspirone Viatrix (Viatrix)
Calamine	Crn, aqueous, BP, 100 g	PSS	Calamine-AFT (AFT)
Cetomacrogol	Crn BP, 500 g	PSS	Cetomacrogol-AFT (AFT)
Ferrous fumarate	Tab 200 mg (65 mg elemental); 100 tab	PSS	Ferro-tab (AFT)
Flucloxacillin	Cap 250 mg; 250 cap Cap 500 mg; 500 cap	PSS	Flucloxacillin-AFT (AFT)
Rosuvastatin	Tab 5 mg; 30 tab Tab 10 mg; 30 tab Tab 20 mg; 30 tab Tab 40 mg; 30 tab	SSS	Rosuvastatin Viatrix (Viatrix)

Looking Forward

This section is designed to alert both pharmacists and prescribers to possible future changes to the Pharmaceutical Schedule. It may also assist pharmacists, distributors and wholesalers to manage stock levels.

Decisions for implementation 1 May 2022

- Clomipramine hydrochloride (Clomipramine Teva) tab 10 mg and 25 mg – removal of Brand Switch Fee
- Lopinavir/Ritonavir (Lopinavir/Ritonavir Mylan) tab 100 mg with ritonavir 25 mg and tab 200 mg with ritonavir 50 mg – removal of Brand Switch Fee

Possible decisions for future implementation 1 May 2022

- Aripiprazole (Aripiprazole Sandoz) tab 5 mg, 10 mg 15 mg, 20 mg and 30 mg – subsidy change

Sole Subsidised Supply (SSS) or Principal Supply Status (PSS) Products – Cumulative to April 2022

Generic Name	Presentation	Brand Name	Expiry Date*
Abacavir sulphate	Tab 300 mg	Ziagen	2022
Abacavir sulphate with lamivudine	Tab 600 mg with lamivudine 300 mg	Kivexa	2022
Acarbose	Tab 50 mg & 100 mg	Accarb	2024
Aciclovir	Eye oint 3%, 4.5 g OP Tab dispersible 200 mg, 400 mg & 800 mg	VirusPOS Lovir	2024 2022
Acitretin	Cap 10 mg & 25 mg	Novatretin	2023
Alendronate sodium	Tab 70 mg	Fosamax	2022
Alendronate sodium with colecalciferol	Tab 70 mg with colecalciferol 5,600	Fosamax Plus	2022
Allopurinol	Tab 100 mg & 300 mg	DP-Allopurinol	2023
Ambrisentan	Tab 5 mg & 10 mg	Ambrisentan Mylan	2023
Amiodarone hydrochloride	inj 50 mg per ml, 3 ml ampoule Tab 100 mg & 200 mg	Max Health Aratac	2022
Amisulpride	Tab 100 mg, 200 mg & 400 mg	Sulprix	2022
Amitriptyline	Tab 10 mg, 25 mg & 50 mg	Arrow-Amitriptyline	2023
Amlodipine	Tab 2.5 mg, 5 mg & 10 mg	Vasorex	2023
Amorolfine	Nail soln 5%, 5 ml OP	MycoNail	2023
Amoxicillin	Grans for oral liq 125 mg per 5 ml Grans for oral liq 250 mg per 5 ml Cap 250 mg & 500 mg	Alphamox 125 Alphamox 250 Alphamox	2023 2022
Amoxicillin with clavulanic acid	Tab 500 mg with clavulanic acid 125 mg	Curam Duo 500/125	2023
Anastrozole	Tab 1 mg	Anatrole	2023
Apomorphine hydrochloride	Inj 10 mg per ml, 5 ml ampoule Inj 10 mg per ml, 2 ml ampoule	Movapo	2023
Aprepitant	Cap 2 x 80 mg and 1 x 125 mg	Emend Tripack	2024
Aqueous cream	Crn, 500 g	GEM Aqueous Cream	2024
Ascorbic acid	Tab 100 mg	Cvite	2022
Asprin	Tab 100 mg Tab dispersible 300 mg	Ethics Aspirin EC Ethics Aspirin	2022
Atazanavir sulphate	Cap 150 mg & 200 mg	Teva	2022
Atenolol	Tab 50 mg & 100 mg	Mylan Atenolol	2024
Atomoxetine	Cap 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg & 100 mg	Generic Partners	2022
Atorvastatin	Tab 10 mg, 20 mg, 40 mg & 80 mg	Lorstat	2024
Atropine sulphate	Inj 600 mcg per ml, 1 ml ampoule Eye drops 1%, 15 ml OP	Martindale Atropt	2024 2023

*Expiry date of the SSS/PSS period is 30 June of the year indicated unless otherwise stated. Please note that SSS/PSS may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply (SSS) or Principal Supply Status (PSS) Products – Cumulative to April 2022

Generic Name	Presentation	Brand Name	Expiry Date*
Azathioprine	Tab 25 mg & 50 mg	Azamun	2022
Azithromycin	Tab 500 mg	Zithromax	2024
Bacillus calmette-guerin vaccine	Inj Mycobacterium bovis BCG (Bacillus Calmette-Guerin), Danish strain 1331, live attenuated, vial with diluent	BCG Vaccine	2024
Baclofen	Inj 2 mg per ml, 5 ml ampoule	Medsurge	2024
Bendroflumethiazide [Bendrofluazide]	Tab 2.5 mg & 5 mg	Arrow-Bendrofluazide	2023
Benzatropine mesylate	Inj 1 mg per ml, 2 ml	Phebra	2023
Benzylpenicillin sodium [Penicillin G]	Inj 600 mg (1 million units) vial	Sandoz	2023
Betahistine dihydrochloride	Tab 16 mg	Serc	2023
Betamethasone dipropionate	Crn & oint 0.05%, 50 g OP	Diprosone	2023
Betamethasone dipropionate with calcipotriol	Oint 500 mcg with calcipotriol 50 mcg per g, 30 g OP Gel 500 mcg with calcipotriol 50 mcg per g, 60 g OP	Daivobet	2024
Betamethasone valerate	Lotn 0.1%, 50 ml OP Oint 0.1%, 50 g OP Crn 0.1%, 50 g OP Scalp app 0.1%, 100 ml OP	Betnovate Beta Ointment Beta Cream Beta Scalp	2024
Bicalutamide	Tab 50 mg	Binarex	2023
Bimatoprost	Eye drops 0.03%, 3 ml OP	Bimatoprost Multichem	2024
Bisacodyl	Suppos 10 mg	Lax-suppositories	2024
Bisoprolol fumarate	Tab 2.5 mg, 5 mg & 10 mg	Bisoprolol Mylan	2023
Blood glucose diagnostic test meter	Meter with 50 lancets, a lancing device and 10 diagnostic test strips, 1 OP	CareSens N CareSens N POP CareSens N Premier	2022
Blood glucose diagnostic test strip	Test strips, 50 test OP	CareSens N CareSens PRO	2022
Blood ketone diagnostic test strip	Test strips, 10 strip OP	KetoSens	2022
Bosentan	Tab 62.5 mg & 125 mg	Bosentan Dr Reddy's	2024
Brimonidine tartrate	Eye drops 0.2%, 5 ml OP	Arrow-Brimonidine	2024
Brinzolamide	Eye drops 1%, 5 ml OP	Azopt	2024
Budesonide	Metered aqueous nasal spray, 50 mcg & 100 mcg per dose, 200 dose OP	SteroClear	2023

*Expiry date of the SSS/PSS period is 30 June of the year indicated unless otherwise stated. Please note that SSS/PSS may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply (SSS) or Principal Supply Status (PSS) Products – Cumulative to April 2022

Generic Name	Presentation	Brand Name	Expiry Date*
Buprenorphine with naloxone	Tab sublingual 2 mg with naloxone 0.5 mg & 8 mg with naloxone 2 mg	Buprenorphine Naloxone BNM	2022
Bupropion hydrochloride	Tab modified-release 150 mg	Zyban	2023
Bezafibrate	Tab 200 mg Tab long-acting 400 mg	Bezalip Bezalip Retard	2024
Caffeine citrate	Oral liq 20 mg per ml (10 mg base per ml), 25 ml OP	Biomed	2022
Calcitriol	Cap 0.25 mcg & 0.5 mcg	Calcitriol-AFT	2022
Calcium carbonate	Tab 1.25 g (500 mg elemental)	Calci-Tab 500	2023
Calcium folinate	Inj 10 mg per ml, 5 ml vial	Calcium Folate Sandoz	2022
Candesartan cilexetil	Tab 4 mg, 8 mg, 16 mg & 32 mg	Candestar	2024
Capecitabine	Tab 150 mg & 500 mg	Capercit	2022
Capsaicin	Crn 0.025%, 45 g OP Crn 0.075%, 45 g OP	Zostrix Zostrix HP	2023
Cefaclor monohydrate	Cap 250 mg Grans for oral liq 125 mg per 5 ml	Ranbaxy-Cefaclor	2022
Cefalexin	Cap 250 mg	Cefalexin ABM	2022
Cefazolin	Inj 500 mg & 1 g vial	AFT	2023
Ceftriaxone	Inj 500 mg & 1 g vial	Ceftriaxone-AFT	2022
Cefuroxime axetil	Tab 250 mg	Zinnat	2022
Cetirizine hydrochloride	Oral liq 1 mg per ml, 200 ml Tab 10 mg	Hisatclear Zista	2024 2022
Cetomacrogol with glycerol	Crn 90% with glycerol 10%, 500 ml OP & 1,000 ml OP	Boucher	2022
Chloramphenicol	Eye oint 1%, 5 g OP Eye drops 0.5%, 10 ml OP	Devatis Chlorofast	2022
Chlorpromazine hydrochloride	Tab 10 mg, 25 mg & 100 mg Inj 25 mg per ml, 2 ml	Largactil	2022
Chlortalidone [chlorthalidone]	Tab 25 mg	Hygroton	2022
Cilazapril	Tab 0.5 mg, 2.5 mg & 5 mg	Zapril	2022
Cinacalcet	Tab 30 mg & 60 mg	Cinacalcet Devatis	2024
Ciprofloxacin	Eye drops 0.3%, 5 ml OP Tab 250 mg, 500 mg & 750 mg	Ciprofloxacin Teva Cipflox	2024 2023
Citalopram hydrobromide	Tab 20 mg	PSM Citalopram	2024
Clarithromycin	Tab 250 mg & 500 mg	Klacid	2024
Clindamycin	Cap hydrochloride 150 mg Inj phosphate 150 mg per ml, 4 ml ampoule	Dalacin C	2022

*Expiry date of the SSS/PSS period is 30 June of the year indicated unless otherwise stated. Please note that SSS/PSS may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply (SSS) or Principal Supply Status (PSS) Products – Cumulative to April 2022

Generic Name	Presentation	Brand Name	Expiry Date*
Clobetasol propionate	Crn 0.05%, 30 g OP Oint 0.05%, 30 g OP Scalp app 0.05%, 30 ml OP	Dermol	2022
Clomipramine hydrochloride	Tab 10 mg & 25 mg	Clomipramine Teva	2024
Clonidine	Patch 2.5 mg, 100 mcg per day Patch 5 mg, 200 mcg per day Patch 7.5 mg, 300 mcg per day	Mylan	2023
Clonidine hydrochloride	Inj 150 mcg per ml, 1 ml ampoule Tab 150 mcg	Medsurge Catapres	2024
Clopidogrel	Tab 75 mg	Clopidogrel Multichem	2022
Clotrimazole	Vaginal crm 1% with applicators, 35 g OP Vaginal crm 2% with applicators, 20 g OP	Clomazol	2022
Coal tar	Soln BP	Midwest	2022
Codeine phosphate	Tab 15 mg, 30 mg & 60 mg	PSM	2023
Colecalciferol	Cap 1.25 mg (50,000 iu)	Vit.D3	2023
Compound electrolytes	Powder for oral soln	Electral	2022
Compound hydroxybenzoate	Soln	Midwest	2022
Condoms	60 mm 49 mm 53 mm, 0.05 mm thickness 53 mm 53 mm, strawberry, red 53 mm, chocolate, brown 56 mm 56 mm, 0.08 mm thickness 56 mm, 0.08 mm thickness, red 56 mm, 0.05 mm thickness 56 mm, chocolate 56 mm, strawberry	Shield XL Gold Knight Moments Gold Knight	30/09/2022
Crotamiton	Crn 10%, 20 g OP	Itch-soothe	2024
Cyclizine hydrochloride	Tab 50 mg	Nausicalm	2024
Cyclizine lactate	Inj 50 mg per ml, 1 ml	Hameln	2022
Cyclophosphamide	Tab 50 mg	Cylconex	2024
Cyproterone acetate	Tab 50 mg & 100 mg	Siterone	2024
Cyproterone acetate with ethinyloestradiol	Tab 2 mg with ethinyloestradiol 35 mcg and 7 inert tabs	Ginet	2023
Darunavir	Tab 400 mg & 600 mg	Darunavir Mylan	2023
Desmopressin acetate	Nasal spray 10 mcg per dos, 6 ml OP	Desmopressin-PH&T	2023
Dexamethasone	Tab 0.5 mg & 4 mg	Dexmethsone	2024

*Expiry date of the SSS/PSS period is 30 June of the year indicated unless otherwise stated. Please note that SSS/PSS may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply (SSS) or Principal Supply Status (PSS) Products – Cumulative to April 2022

Generic Name	Presentation	Brand Name	Expiry Date*
Dexamethasone phosphate	Inj 4 mg per ml, 1 ml & 2 ml ampoule	Dexamethasone Phosphate Panpharma	2022
Dexamfetamine sulfate	Tab 5 mg	PSM	2024
Diazepam	Tab 2 mg & 5 mg	Arrow-Diazepam	2023
Diclofenac	Eye drops 0.1%, 5 ml OP	Voltaren Ophtha	2024
Diclofenac sodium	Tab EC 25 mg & 50 mg	Diclofenac Sandoz	2024
Digoxin	Tab 62.5 mcg Tab 240 mcg	Lanoxin PG Lanoxin	2022
Dihydrocodeine tartrate	Tab long-acting 60 mg	DHC Continus	2022
Diltiazem hydrochloride	Cap long-acting 180 mg & 240 mg	Cardizem CD	2024
Dimethicone	Crn 5% pump bottle, 500 ml OP Lotn 4%, 200 ml OP	healthE Dimethicone 5% healthE Dimethicone 4%	2022
Diphtheria, tetanus and pertussis vaccine	Inj 2 IU diphtheria toxoid with 20 IU tetanus toxoid, 8 mcg pertussis toxoid, 8 mcg pertussis filamentous haemagglutinin and 2.5 mcg pertactin in 0.5 ml syringe	Boostrix	2024
Diphtheria, tetanus, pertussis and polio vaccine	Inj 30 IU diphtheria toxoid with 40 IU tetanus toxoid, 25 mcg pertussis toxoid, 25 mcg pertussis filamentous haemagglutinin, 8 mcg pertactin and 80 D-antigen units poliomyelitis virus in 0.5ml syringe	Infanrix IPV	2024
Diphtheria, tetanus, pertussis, polio, hepatitis B and haemophilus influenzae type B vaccine	Inj 30 IU diphtheria toxoid with 40 IU tetanus toxoid, 25 mcg pertussis toxoid, 25 mcg pertussis filamentous haemagglutinin, 8 mcg pertactin, 80 D-AgU polio virus, 10 mcg hepatitis B surface antigen in 0.5ml syringe	Infanrix-hexa	2024
Dipyridamole	Tab long-acting 150 mg	Pytazen SR	2022
Disulfiram	Tab 200 mg	Antabuse	2024
Docusate sodium	Tab 50 mg & 120 mg	Coloxyl	2023
Domperidone	Tab 10 mg	Pharmacy Health	2024
Donepezil hydrochloride	Tab 5 mg & 10 mg	Donepezil-Rex	2023
Dorzolamide with timolol	Eye drops 2% with timolol 0.5%, 5 ml OP	Dortimopt	2024
Dual blood glucose and blood ketone diagnostic test meter	Meter with 50 lancets, a lancing device and 10 blood glucose diagnostic test strips, 1 OP	CareSens Dual	2022

*Expiry date of the SSS/PSS period is 30 June of the year indicated unless otherwise stated. Please note that SSS/PSS may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply (SSS) or Principal Supply Status (PSS) Products – Cumulative to April 2022

Generic Name	Presentation	Brand Name	Expiry Date*
Efavirenz with emtricitabine and tenofovir disoproxil	Tab 600 mg with emtricitabine 200 mg and tenofovir disoproxil 245 mg (300 mg as a maleate)	Mylan	2022
Emtricitabine	Cap 200 mg	Emtriva	2022
Emtricitabine with tenofovir disoproxil	Tab 200 mg with tenofovir disoproxil 245 mg (300.6 mg as a succinate)	Teva	2022
Emulsifying ointment	Oint BP	Emulsifying Ointment ADE	2023
Enalapril maleate	Tab 5 mg, 10 mg & 20 mg	Acetec	2022
Entacapone	Tab 200 mg	Comtan	2024
Epoetin alfa	Inj 1,000 iu in 0.5 ml, syringe Inj 2,000 iu in 1 ml, syringe Inj 3,000 iu in 0.3 ml, syringe Inj 4,000 iu in 0.4 ml, syringe Inj 5,000 iu in 0.5 ml, syringe Inj 6,000 iu in 0.6 ml, syringe Inj 8,000 iu in 0.8 ml, syringe Inj 10,000 iu in 1 ml, syringe Inj 40,000 iu in 1 ml, syringe	Binocrit	2022
Erythromycin (as lactobionate)	Inj 1 g vial	Erythrocin IV	2022
Escitalopram	Tab 10 mg & 20 mg	Escitalopram (Ethics)	2024
Etanercept	Inj 25 mg Inj 50 mg autoinjector Inj 50 mg prefilled syringe	Enbrel	2024
Ethinylestradiol and norethisterone	Tab 35 mcg with norethisterone 1 mg and 7 inert tab	Brevinor 1/28	2022
Etoposide	Cap 50 mg & 100 mg	Vepesid	2022
Ezetimibe	Tab 10 mg	Ezetimibe Sandoz	2023
Febuxostat	Tab 80 mg & 120 mg	Febuxostat multichem	2023
Felodipine	Tab long-acting 5 mg Tab long-acting 10 mg	Felo 5 ER Felo 10 ER	2024
Fentanyl	Inj 50 mcg per ml, 2ml ampoule Inj 50 mcg per ml, 10 ml ampoule Patch 12.5 mcg per hour Patch 25 mcg per hour Patch 50 mcg per hour Patch 75 mcg per hour Patch 100 mcg per hour	Boucher and Muir Fentanyl Sandoz	2024
Ferrous sulfate	Oral liq 30 mg (6 mg elemental) per ml	Ferodan	2022
Filgrastim	Inj 300 mcg per 0.5 ml & 480 mcg per 0.5 ml	Nivestim	2024

*Expiry date of the SSS/PSS period is 30 June of the year indicated unless otherwise stated. Please note that SSS/PSS may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply (SSS) or Principal Supply Status (PSS) Products – Cumulative to April 2022

Generic Name	Presentation	Brand Name	Expiry Date*
Finasteride	Tab 5 mg	Ricit	2023
Flecainide acetate	Tab 50 mg Cap long-acting 100 mg & 200 mg	Flecainide BNM Flecainide Controlled Release Teva	2022
Flucloxacillin	Grans for oral liq 25 mg per ml Grans for oral liq 50 mg per ml Inj 1 g vial	AFT	2024
		Flucil	2023
Fluconazole	Cap 50 mg, 150 mg & 200 mg	Mylan	2023
Fluorouracil sodium	Crn 5%, 20 g OP	Efudix	2024
Fluticasone	Aerosol inhaler 50 mcg, 125 mcg & 250 mcg per dose, 120 dose OP	Flixotide	2023
Fluticasone propionate	Metered aqueous nasal spray, 50 mcg per dose, 120 dose OP	Flixonase Hayfever & Allergy	2024
Fluticasone with salmeterol	Aerosol inhaler 50 mcg with salmeterol 25 mcg & 125 mcg with salmeterol 25 mcg, 120 dose OP	Seretide	2023
Folic acid	Tab 5 mg	Folic Acid Mylan	2024
Furosemide [frusemide]	Tab 40 mg Inj 10 mg per ml, 25 ml ampoule Oral liq 10 mg per ml, 30 ml OP Inj 10 mg per ml, 2 ml ampoule	IPCA-Frusemide	2024
		Lasix	2022
		Frusemide-Baxter	
Gabapentin	Cap 100 mg, 300 mg & 400 mg	Nupentin	2024
Gliobenclamide	Tab 5 mg	Daonil	2024
Gliclazide	Tab 80 mg	Glizide	2023
Glipizide	Tab 5 mg	Minidiab	2024
Glucagon hydrochloride	Inj 1 mg syringe kit	Glucagen Hypokit	2023
Glucose [Dextrose]	Inj 50%, 10 ml ampoule Inj 50%, 90 ml bottle	Biomed	2023
Glycerin with sodium saccharin	Suspension	Ora-Sweet SF	2022
Glycerin with sucrose	Suspension	Ora-Sweet	2022
Glycerol	Liquid	healthE Glycerol BP	2023
Glyceryl trinitrate	Oint 0.2%, 30 g OP	Rectogesic	2024
Goserelin	Implant 3.6 mg & 10.8 mg, syringe	Teva	2023
Haloperidol	Inj 5 mg per ml, 1 ml ampoule Oral liq 2 mg per ml Tab 500 mcg, 1.5 mg & 5 mg	Serenace	2022
Hepatitis A vaccine	Inj 1440 ELISA units in 1 ml syringe Inj 720 ELISA units in 0.5 ml syringe	Havrix	2024
		Havrix Junior	
Hepatitis B recombinant vaccine	Inj 20 mcg per 1 ml prefilled syringe	Engerix-B	2024

*Expiry date of the SSS/PSS period is 30 June of the year indicated unless otherwise stated. Please note that SSS/PSS may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply (SSS) or Principal Supply Status (PSS) Products – Cumulative to April 2022

Generic Name	Presentation	Brand Name	Expiry Date*
Human papillomavirus (6, 11, 16, 18, 31, 33, 45, 52 and 58) vaccine [HPV]	Inj 270 mg in 0.5 ml syringe	Gardasil 9	2024
Hydrocortisone	Inj 100 mg vial Crm 1%, 500 g Crm 1%, 100 g OP	Solu-Cortef Hydrocortisone (PSM)	2024 2022
Hydrocortisone and paraffin liquid and lanolin	Lotn 1% with paraffin liquid 15.9% and lanolin 0.6%	DP Lotn HC	2023
Hydrocortisone butyrate	Oint 0.1%, 100 g OP Scalp lotn 0.1%, 100 ml OP Milky emuls 0.1%, 100 ml OP	Locoid Locoid Crelo	2024
Hydrocortisone with miconazole	Crm 1% with miconazole 2%, 15 g OP	Micreme H	2024
Hydroxyurea [hydroxycarbamide]	Cap 500 mg	Devatis	2023
Hyoscine butylbromide	Tab 10 mg Inj 20 mg, 1 ml	Buscopan	2023
Ibuprofen	Oral liq 20 mg per ml, 200 ml Tab long-acting 800 mg Tab 200 mg	Ethics Brufen SR Relieve	2024
Iloprost	Nebuliser soln 10 mcg per ml, 2 ml	Ventavis	2022
Imatinib mesylate	Cap 100 mg & 400 mg	Imatinib-Rex	2023
Indapamide	Tab 2.5 mg	Dapa-Tabs	2023
Intra-uterine device	IUD 29.1 mm length x 23.2 mm width IUD 33.6 mm length x 29.9 mm width IUD 35.5 mm length x 19.6 mm width	Choice TT380 Short Choice TT380 Standard Choice Load 375	2022
Ipratropium bromide	Aqueous nasal spray, 0.03%, 15 ml OP Nebuliser soln, 250 mcg per ml, 2 ml ampoule	Univent	2023 2022
Isoniazid	Tab 100 mg	PSM	2024
Isoniazid with rifampicin	Tab 100 mg with rifampicin 150 mg Tab 150 mg with rifampicin 300 mg	Rifinah	2024
Isosorbide mononitrate	Tab 20 mg Tab long-acting 40 mg Tab long-acting 60 mg	ISMO 20 ISMO 40 Retard Duride	2023
Isotretinoin	Cap 5 mg, 10 mg & 20 mg	Oratane	2024
Ispaghula (psyllium) husk	Powder for oral soln, 500 g OP	Konsyl-D	2023
Itraconazole	Cap 100 mg	Itrazole	2022
Ketoconazole	Shampoo 2%, 100 ml OP	Sebizole	2023
Labetalol	Tab 100 mg & 200 mg	Trandate	2024

*Expiry date of the SSS/PSS period is 30 June of the year indicated unless otherwise stated. Please note that SSS/PSS may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply (SSS) or Principal Supply Status (PSS) Products – Cumulative to April 2022

Generic Name	Presentation	Brand Name	Expiry Date*
Lactulose	Oral liq 10 g per 15 ml	Laevolac	2022
Lamivudine	Tab 100 mg Tab 150 mg	Zetlam Lamivudine Alphapharm	2023
Lamotrigine	Tab dispersible 25 mg, 50 mg & 100 mg	Logem	2022
Lansoprazole	Cap 15 mg & 30 mg	Lanzol Relief	2024
Latanoprost	Eye drop 0.005%, 2.5 ml OP	Teva	2024
Latanoprost with timolol	Eye drops 0.005% with timolol 0.5%, 2.5 ml OP	Arrow - Lattim	2023
Leflunomide	Tab 10 mg & 20 mg	Arava	2023
Letrozole	Tab 2.5 mg	Letrole	2024
Levetiracetam	Tab 250 mg, 500 mg, 750 mg and 1,000 mg	Everet	2022
Levodopa with carbidopa	Tab long-acting 200 mg with carbidopa 50 mg Tab 100 mg with carbidopa 25 mg & 250 mg with carbidopa 25 mg	Sinemet CR Sinemet	2023
Levomepromazine hydrochloride	Inj 25 mg per ml, 1 ml ampoule	Nozinan	2022
Levomepromazine maleate	Tab 25 mg & 100 mg	Nozinan	2022
Levonorgestrel	Tab 1.5 mg Subdermal implant (2 x 75 mg rods) Tab 30 mcg Intra-uterine device system 52 mg Intra-uterine device system 13.5 mg	Postinor-1 Jadelle Microlut Mirena Jaydess	2022 2023 2022 31/10/2022
Lidocaine [Lignocaine]	Gel 2%, 11 ml urethral syringe	Instillagel Lido	2022
Lidocaine [lignocaine] hydrochloride	Inj 2%, 5 ml ampoule Inj 1%, 20 ml vial Inj 2%, 20 ml vial	Lidocaine-Baxter Lidocaine-Claris Lidocaine-Baxter	2022
Lithium carbonate	Tab long-acting 400 mg	Priadel	2024
Loperamide hydrochloride	Cap 2 mg	Diamide Relief	2022
Lopinavir with ritonavir	Tab 100 mg with ritonavir 25 mg Tab 200 mg with ritonavir 50 mg	Lopinavir/Ritonavir Mylan	2024
Loratadine	Oral liq 1 mg per ml Tab 10 mg	Haylor syrup Lorafix	2022
Lorazepam	Tab 1 mg & 2.5 mg	Ativan	2024
Losartan potassium	Tab 12.5 mg, 25 mg, 50 mg & 100 mg	Losartan Actavis	2023
Macrogol 3350 with potassium chloride, sodium bicarbonate and sodium chloride	Powder for oral soln 13.125 g with potassium chloride 46.6 mg, sodium bicarbonate 178.5 mg and sodium chloride 350.7 mg	Molaxole	2023

*Expiry date of the SSS/PSS period is 30 June of the year indicated unless otherwise stated. Please note that SSS/PSS may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply (SSS) or Principal Supply Status (PSS) Products – Cumulative to April 2022

Generic Name	Presentation	Brand Name	Expiry Date*
Magnesium sulphate	Inj 2 mmol per ml, 5 ml ampoule	Martindale	2023
Measles, mumps and rubella vaccine	Inj, measles virus 1,000 CCID ₅₀ , mumps virus 5,012 CCID ₅₀ , Rubella virus 1,000 CCID ₅₀ ; prefilled syringe/ampoule of diluent 0.5 ml	Priorix	2024
Mebendazole	Tab 100 mg	Vermox	2024
Mebeverine hydrochloride	Tab 135 mg	Colofac	2023
Medroxyprogesterone acetate	Inj 150 mg per ml, 1 ml syringe	Depo-Provera	2022
Melatonin	Tab modified-release 2 mg	Vigisom	2024
Meningococcal (groups A, C, Y and W-135) conjugate vaccine	Inj 4 mcg of each meningococcal polysaccharide conjugated to a total of approximately 48 mcg of diphtheria toxoid carrier per 0.5 ml vial	Menactra	2024
Mercaptopurine	Tab 50 mg	Puri-nethol	2022
Mesalazine	Tab long-acting 500 mg	Pentasa	2023
Mesna	Tab 400 mg & 600 mg	Uromitexan	2022
Methadone	Oral liq 2 mg per ml Oral liq 5 mg per ml Oral liq 10 mg per ml	Biodone Biodone Forte Biodone Extra Forte	2024
Methadone hydrochloride	Tab 5 mg	Methatabs	2022
Methotrexate	Tab 2.5 mg & 10 mg Inj 100 mg per ml, 50 ml vial	Trexate Methotrexate Ebewe	2024 2023
Methylcellulose	Powder Suspension	Midwest Ora Plus	2022
Methylcellulose with glycerin and sodium saccharin	Suspension	Ora Blend SF	2022
Methylcellulose with glycerin and sucrose	Suspension	Ora Blend	2022
Methyl hydroxybenzoate	Powder	Midwest	2022
Methylprednisolone aceponate	Crn & oint 0.1%, 15 g OP	Advantan	2023
Metoclopramide hydrochloride	Tab 10 mg Inj 5 mg per ml, 2 ml ampoule	Metoclopramide Actavis 10 Pfizer	2023 2022
Metoprolol tartrate	Tab 50 mg & 100 mg	IPCA-Metoprolol	2024
Metronidazole	Tab 200 mg & 400 mg	Metrogyl	2023
Metyrapone	Cap 250 mg	Metopirone	2023
Miconazole	Oral gel 20 mg per g, 40 g OP	Decozol	2024

*Expiry date of the SSS/PSS period is 30 June of the year indicated unless otherwise stated. Please note that SSS/PSS may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply (SSS) or Principal Supply Status (PSS) Products – Cumulative to April 2022

Generic Name	Presentation	Brand Name	Expiry Date*
Miconazole nitrate	Crn 2%, 15 g OP Vaginal crm 2% with applicator, 40 g OP	Multichem Micreme	2023
Mirtazapine	Tab 30 mg & 45 mg	Noumed	2024
Moclobemide	Tab 150 mg & 300 mg	Aurorix	2024
Modafinil	Tab 100 mg	Modavigil	2024
Mometasone furoate	Crn 0.1%, 15 g OP Crn 0.1%, 50 g OP Oint 0.1%, 15 g OP Oint 0.1%, 50 g OP Lotn 0.1%, 30 ml OP	Elocon Alcohol Free Elocon	2024
Montelukast	Tab 4 mg, 5 mg & 10 mg	Montelukast Mylan	2022
Morphine sulphate	Tab immediate-release 10 mg & 20 mg Cap long-acting 10 mg, 30 mg, 60 mg & 100 mg	Sevredol m-Eslon	2023 2022
Moxifloxacin	Tab 400 mg	Avelox	2023
Multivitamins	Tab (BPC cap strength)	Mvite	2022
Nadolol	Tab 40 mg & 80 mg	Nadolol BNM	2024
Naltrexone hydrochloride	Tab 50 mg	Naltraccord	2023
Naproxen	Tab 250 mg Tab 500 mg Tab long-acting 750 mg Tab long-acting 1 g	Noflam 250 Noflam 500 Naprosyn SR 750 Naprosyn SR 1000	2024
Neostigmine metilsulfate	Inj 2.5 mg per ml, 1 ml ampoule	Max Health	2024
Nevirapine	Tab 200 mg	Nevirapine Alphapharm	2024
Nicorandil	Tab 10 mg & 20 mg	Ikorel	2022
Nitrofurantoin	Cap modified-release 100 mg	Macrobid	2023
Norethisterone	Tab 350 mcg	Noriday 28	2024
Nortriptyline hydrochloride	Tab 10 mg & 25 mg	Norpress	2022
Nystatin	Oral liq 100,000 u per ml, 24 ml OP Vaginal crm 100,000 u per 5 g with applicator(s), 75 g OP	Nilstat	2023
Octreotide long-acting	Inj depot 10 mg, 20 mg & 30 mg prefilled syringe	Octreotide Depot Teva	2024
Oestriol	Crn 1 mg per g with applicator, 15 g OP Pessaries 500 mcg Tab 2 mg	Ovestin Ovestin	2023
Olanzapine	Orodispersible tab 5 mg & 10 mg Tab 2.5 mg, 5 mg and 10 mg	Zypine ODT Zypine	2023

*Expiry date of the SSS/PSS period is 30 June of the year indicated unless otherwise stated. Please note that SSS/PSS may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply (SSS) or Principal Supply Status (PSS) Products – Cumulative to April 2022

Generic Name	Presentation	Brand Name	Expiry Date*
Olopatadine	Eye drops 0.1%, 5 ml OP	Olopatadine Teva	2022
Omeprazole	Cap 10 mg	Omeprazole actavis 10	2023
	Cap 20 mg	Omeprazole actavis 20	
	Cap 40 mg	Omeprazole actavis 40	
	Inj 40 mg ampoule with diluent	Dr Reddy's Omeprazole	2022
Ondansetron	Tab disp 4 mg & 8 mg	Ondansetron ODT-DRLA	2023
	Tab 4 mg & 8 mg	Onrex	2022
Ornidazole	Tab 500 mg	Arrow-Ornidazole	2024
Orphenadrine citrate	Tab 100 mg	Norflex	2024
Oxycodone hydrochloride	Cap immediate-release 5 mg, 10 mg & 20 mg	OxyNorm	2024
	Oral liq 5 mg per 5 ml		
Oxytocin with ergometrine maleate	Inj 5 iu with ergometrine maleate 500 mcg per ml, 1 ml	Syntometrine	2024
Pantoprazole	Tab EC 20 mg & 40 mg	Panzop Relief	2022
Paracetamol	Tab 500 mg-bottle pack	Noumed Paracetamol	2024
	Tab 500 mg-blister pack	Pacimol	
	Oral liq 120 mg per 5 ml	Paracare	2023
	Oral liq 250 mg per 5 ml	Paracare Double Strength	
Paraffin	White soft, 500 g & 2,500 g	healthE	2022
Paroxetine	Tab 20 mg	Loxamine	2022
Perhexiline maleate	Tab 100 mg	Pexsig	2022
Perindopril	Tab 2 mg & 4 mg	Coversyl	2024
Permethrin	Crn 5%, 30 g OP	Lyderm A-Scabies	2023
	Lotn 5%, 30 ml OP		
Pethidine hydrochloride	Tab 50 mg	PSM	2024
Phenoxymethylpenicillin (penicillin V)	Cap 250 mg	Ciicaine VK	2024
	Cap 500 mg		
	Grans for oral liq 125 mg per 5 ml	AFT	2022
	Grans for oral liq 250 mg per 5 ml		
Pimecrolimus	Crn 1%, 15 g OP	Elidel	2023
Pine tar with trolamine laurilsulfate and fluorescein	Soln 2.3% with trolamine laurilsulfate and fluorescein sodium	Pinetarsol	2023
Pioglitazone	Tab 15 mg, 30 mg & 45 mg	Vexazone	2024

*Expiry date of the SSS/PSS period is 30 June of the year indicated unless otherwise stated. Please note that SSS/PSS may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply (SSS) or Principal Supply Status (PSS) Products – Cumulative to April 2022

Generic Name	Presentation	Brand Name	Expiry Date*
Pneumococcal (PCV10) conjugate vaccine	Inj 1 mcg of pneumococcal polysaccharide serotypes 1, 5, 6B, 7F, 9V, 14 and 23F; 3 mcg of pneumococcal polysaccharide serotypes 4, 18C and 19F in 0.5 ml prefilled syringe	Synflorix	2024
Pneumococcal (PPV23) polysaccharide vaccine	Inj 575 mcg in 0.5 ml prefilled syringe (25 mcg of each 23 pneumococcal serotype)	Pneumovax 23	2024
Poliomyelitis vaccine	Inj 80D antigen units in 0.5 ml syringe	IPOL	2024
Poloxamer	Oral drops 10%, 30 ml OP	Coloxyl	2023
Potassium iodate	Tab 253 mcg (150 mcg elemental iodine)	NeuroTabs	2023
Povidone iodine	Antiseptic solution 10%, 100 ml Oint 10%, 65 g OP	Riodone Betadine	2024 2023
Pramipexole hydrochloride	Tab 0.25 mg & 1 mg	Ramipex	2022
Pravastatin	Tab 20 mg & 40 mg	Pravastatin Mylan	2023
Prednisolone	Oral liq 5 mg per ml, 30 ml OP	Redipred	2024
Prochlorperazine	Tab 5 mg	Nausafix	2023
Propranolol	Tab 10 mg Tab 40 mg	Drofate IPCA-Propranolol	2024
Pyridostigmine bromide	Tab 60 mg	Mestinon	2022
Pyridoxine hydrochloride	Tab 25 mg	Vitamin B6 25	2023
Quetiapine	Tab 25 mg, 100 mg, 200 mg & 300 mg	Quetapel	2023
Quinapril	Tab 5 mg Tab 10 mg Tab 20 mg	Arrow-Quinapril 5 Arrow Quinapril 10 Arrow-Quinapril 20	2024
Quinapril with hydrochlorothiazide	Tab 10 mg with hydrochlorothiazide 12.5 mg Tab 20 mg with hydrochlorothiazide 12.5 mg	Accuretic 10 Accuretic 20	2024
Rifampicin	Cap 150 mg & 300 mg Oral liq 100 mg per 5 ml	Rifadin	2023
Rifaximin	Tab 550 mg	Xifaxan	2023
Riluzole	Tab 50 mg	Rilutek	2024
Risedronate sodium	Tab 35 mg	Risedronate Sandoz	2022
Risperidone	Tab 0.5 mg, 1 mg, 2 mg, 3 mg & 4 mg Oral liq 1 mg per ml	Risperidone (Teva) Risperon	2023
Ritonavir	Tab 100 mg	Norvir	2022

*Expiry date of the SSS/PSS period is 30 June of the year indicated unless otherwise stated. Please note that SSS/PSS may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply (SSS) or Principal Supply Status (PSS) Products – Cumulative to April 2022

Generic Name	Presentation	Brand Name	Expiry Date*
Rituximab	Inj 100 mg per 10 ml vial & 500 mg per 50 ml vial	Riximyo	30/09/2023
Rivastigmine	Patch 4.6 mg per 24 hour Patch 9.5 mg per 24 hour	Rivastigmine Patch BNM 5 Rivastigmine Patch BNM 10	2024
Rizatriptan	Tab orodispersible 10 mg	Rizamelt	2023
Ropinirole hydrochloride	Tab 0.25 mg, 1 mg, 2 mg & 5 mg	Ropin	2022
Rotavirus oral vaccine	Oral susp live attenuated human rotavirus 1,000,000 CCID50 per dose, prefilled oral applicator	Rotarix	2024
Roxithromycin	Tab 150 mg & 300 mg	Arrow-Roxithromycin	2022
Salbutamol	Oral liq 400 mcg per ml, 150 ml Nebuliser soln 1 mg per ml, 2.5 ml ampoule Nebuliser soln 2 mg per ml, 2.5 ml ampoule	Ventolin Asthalin	2024
Salbutamol with ipratropium bromide	Nebuliser soln, 2.5 mg with ipratropium bromide 0.5 mg per vial, 2.5 ml ampoule	Duolin	2024
Sertraline	Tab 50 mg & 100 mg	Setrona	2022
Sildenafil	Tab 25 mg, 50 mg & 100 mg	Vedafil	2024
Simvastatin	Tab 10 mg, 20 mg, 40 mg & 80 mg	Simvastatin Mylan	2023
Sodium bicarbonate	Powder BP	Midwest	2022
Sodium chloride	Inj 0.9%, 5 ml ampoule, 10 ml ampoule & 20 ml ampoule Nebuliser soln, 7%, 90 ml OP	Fresenius Kabi Biomed	2022
Sodium citrate with sodium lauryl sulphoacetate	Enema 90 mg with sodium lauryl sulphoacetate 9 mg per ml, 5 ml	Micolette	2022
Sodium citro-tartrate	Grans eff 4 g sachets	Ural	2023
Sodium cromoglicate	Eye drops 2%, 5 ml OP	Rexacrom	2022
Sodium fusidate [Fusidic acid]	Crn 2%, 5 g OP Oint 2%, 5 g OP	Foban	2024
Sodium hyaluronate [hyaluronic acid]	Eye drops 1 mg per ml, 10 ml OP	Hylo-Fresh	2024
Solifenacin succinate	Tab 5 mg & 10 mg	Solifenacin Mylan	2024
Somatropin (Omnitrope)	Inj 5 mg, 10 mg & 15 mg cartridge	Omnitrope	2024
Sotalol	Tab 80 mg & 160 mg	Mylan	2022
Spironolactone	Oral liq 5 mg per ml, 25 ml OP	Biomed	2022
Sulfasalazine	Tab EC 500 mg	Salazopyrin EN	2022

*Expiry date of the SSS/PSS period is 30 June of the year indicated unless otherwise stated. Please note that SSS/PSS may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply (SSS) or Principal Supply Status (PSS) Products – Cumulative to April 2022

Generic Name	Presentation	Brand Name	Expiry Date*
Sumatriptan	Tab 50 mg & 100 mg Inj 12 mg per ml, 0.5 ml prefilled pen, 2 OP	Sumagran Imigran	2024 2022
Sunscreen, proprietary	Lotn, 200 g OP	Marine Blue Lotion SPF 50+	2022
Syrup (pharmaceutical grade)	Liq	Midwest	2022
Tacrolimus	Oint 0.1%, 30 g OP	Zematop	2023
Taliglucerase alfa	Inj 200 unit vial	Elelyso	2023
Tamoxifen citrate	Tab 10 mg & 20 mg	Tamoxifen Sandoz	2023
Tamsulosin hydrochloride	Cap 400 mcg	Tamsulosin-Rex	2022
Temazepam	Tab 10 mg	Normison	2023
Temozolomide	Cap 5 mg, 20 mg, 100 mg, 140 mg & 250 mg	Temaccord	2022
Tenoxicam	Tab 20 mg	Tilocotil	2022
Terbinafine	Tab 250 mg	Deolate	2023
Teriflunomide	Tab 14 mg	Aubagio	2023
Tetrabenazine	Tab 25 mg	Motetis	2022
Theophylline	Tab long-acting 250 mg Oral liq 80 mg per 15 ml	Nuelin-SR Nuelin	2022
Timolol	Eye drops 0.25% & 0.5%, 5 ml OP	Arrow-Timolol	2023
Tobramycin	Inj 40 mg per ml, 2 ml vial Solution for inhalation 60 mg per ml, 5 ml	Tobramycin Mylan Tobramycin BNM	2024 2023
Tramadol hydrochloride	Cap 50 mg Tab sustained-release 100 mg Tab sustained-release 150 mg Tab sustained-release 200 mg	Arrow-Tramadol Tramal SR 100 Tramal SR 150 Tramal SR 200	2023
Tranexamic acid	Tab 500 mg	Mercury Pharma	2022
Travoprost	Eye drops 0.004%, 2.5 ml OP	Travatan	2024
Tretinoin	Crn 0.5 mg per g, 50 g OP	ReTrieve	2024
Triamcinolone acetoneide	Inj 10 mg per ml, 1 ml ampoule Inj 40 mg per ml, 1 ml ampoule Paste 0.1%, 5 g OP Crn & oint 0.02%, 100 g OP	Kenacort-A 10 Kenacort-A 40 Kenalog in Orabase Aristocort	2023
Trimethoprim	Tab 300 mg	TMP	2024
Trimethoprim with sulphamethoxazole [co-trimoxazole]	Tab trimethoprim 80 mg and sulphamethoxazole 400 mg	Trisul	2024
Tuberculin PPD [Mantoux] test	Inj 5 TU per 0.1 ml, 1 ml vial	Tubersol	2024

*Expiry date of the SSS/PSS period is 30 June of the year indicated unless otherwise stated. Please note that SSS/PSS may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply (SSS) or Principal Supply Status (PSS) Products – Cumulative to April 2022

Generic Name	Presentation	Brand Name	Expiry Date*
Ursodeoxycholic acid	Cap 250 mg	Ursosan	2023
Valaciclovir	Tab 500 mg & 1,000 mg	Valclovir	2024
Valganciclovir	Tab 450 mg	Valganciclovir Mylan	2024
Vancomycin	Inj 500 mg vial	Mylan	2023
Varenicline tartrate	Tab 0.5 mg x 11 and 1 mg x 42, 53 OP Tab 1 mg	Varenicline Pfizer	2024
Varicella vaccine [Chickenpox vaccine]	Inj 1350 PFU prefilled syringe	Varivax	2024
Zinc sulphate	Cap 137.4 mg (50 mg elemental)	Zincaps	2022
Zoledronic acid	Inj 4 mg per 5 ml, vial	Zoledronic Acid Mylan	2024
	Inj 0.05 mg per ml, 100 ml, vial, 100 ml OP	Aclasta	2022
Zopiclone	Tab 7.5 mg	Zopiclone Actavis	2024

April 2022 changes are in bold type

**Expiry date of the SSS/PSS period is 30 June of the year indicated unless otherwise stated. Please note that SSS/PSS may have been awarded for a wider scope than just those presentation(s) listed in the above table.*

Check your Schedule for full details
Schedule page ref

Subsidy
(Mnfr's price)
\$ Per

Brand or
Generic Mnfr
✓ fully subsidised

New Listings

Effective 1 April 2022

58 OIL IN WATER EMULSION
* Crm..... 2.04 500 g ✓ **Fatty Cream AFT**

240 PHARMACY SERVICES
May only be claimed once per patient.
* Brand switch fee..... 4.50 1 fee
✓ **BSF Vigisom**
✓ **BSF Cinacalcet**
Devatis
✓ **BSF Comtan**

Note – the Pharmacode for BSF Vigisom is 2634112. The Pharmacode for BSF Cinacalcet Devatis is 2634120. The Pharmacode for BSF Comtan is 2634139.

261 AMINO ACID FORMULA – Special Authority see SA2092 – Hospital pharmacy [HP3]
Powder..... 43.60 400 g OP ✓ **Alfamino**
Note – this listing is for Pharmacode 2632187.

261 AMINO ACID FORMULA – Special Authority see SA2092 – Hospital pharmacy [HP3]
Powder..... 43.60 400 g OP ✓ **Alfamino Junior**
Note – this listing is for Pharmacode 2634848.

Changes to Restrictions, Chemical Names and Presentations Effective 1 April 2022

78	CINACALCET – Special Authority see SA1618 – Retail pharmacy (addition of brand switch fee payable) Tab 30 mg.....42.06 28 ✓ Cinacalcet Devatis a) Wastage claimable b) Brand switch fee payable
78	ZOLEDRONIC ACID (amended restriction criteria – amended criteria shown only) Inj 4 mg per 5 ml, vial – Special Authority see SA2109 2031 – Retail pharmacy 18.00 1 ✓ Zoledronic acid Mylan <div style="border: 1px solid black; padding: 2px; display: inline-block;"> SA2109 2031 </div> Special Authority for Subsidy Initial application — (symptomatic hypercalcaemia*) from any relevant practitioner. Approvals valid without further renewal unless notified where the patient has symptomatic hypercalcaemia. Note: Indications marked with * are unapproved indications. Initial application — (early breast cancer*) from any relevant practitioner. Approvals valid for 2-years 3 years for applications meeting the following criteria: All of the following: 1 Treatment to be used as adjuvant therapy for early breast cancer; and 2 Patient has been amenorrhoeic for 12 months or greater, either naturally or induced, with endocrine levels consistent with a postmenopausal state; and 3 Treatment to be administered at a minimum interval of 6-monthly for a maximum of 2-years 3 years . Note: Indications marked with * are unapproved indications.
114	ZOLEDRONIC ACID (amended restriction criteria – new criteria shown only) Inj 0.05 mg per ml, 100 ml, vial – Special Authority see SA2110 1780 – Retail pharmacy60.00 100 ml OP ✓ Aclasta <div style="border: 1px solid black; padding: 2px; display: inline-block;"> SA2110 1780 </div> Special Authority for Subsidy Initial application — (spinal cord injury*) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 Patient has experienced an acute traumatic spinal cord injury in the last six months; and 2 Patient is being managed by a specialist spinal acute care and rehabilitation unit; and 3 The patient will not be prescribed more than 5 mg of zoledronic acid in a 12-month period. Note: Indications marked with * are unapproved indications. Renewal — (spinal cord injury*) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 The patient will not be prescribed more than 5 mg of zoledronic acid in a 12-month period; and 2 The patient has not received more than two doses of zoledronic acid for this indication. The patient must not have had more than 1 prior approval. Note: No further renewals will be subsidised. A maximum of 2 vials of zoledronic acid treatment for spinal cord injury will be subsidised. Indications marked with * are unapproved indications.

▲ Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber or pharmacist

* Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details
Schedule page ref

Subsidy
(Mnfr's price)
\$ Per

Brand or
Generic Mnfr
✓ fully subsidised

Changes to Restrictions – effective 1 April 2022 (continued)

116	FEBUXOSTAT – Special Authority see SA2054 – Retail pharmacy – Brand switch fee payable (removal of brand switch fee payable)			
	Tab 80 mg.....	20.00	28	✓ Febuxostat multichem
	Tab 120 mg.....	20.00	28	✓ Febuxostat multichem
118	ENTACAPONE – Brand switch fee payable (addition of brand switch fee payable)			
	▲ Tab 200 mg.....	18.04	100	✓ Comtan
128	PREGABALIN (removal of stat)			
	Note: Not subsidised in combination with subsidised gabapentin			
	* Cap 150 mg	4.01	56	✓ Lyrice ✓ Pregabalin Pfizer
	* Cap 300 mg	7.38	56	✓ Pregabalin Pfizer
137	MELATONIN – Special Authority see SA1666 – Retail pharmacy – Brand switch fee payable (addition of brand switch fee payable)			
	Tab modified-release 2 mg – No more than 5 tab per day.....	11.50	30	✓ Vigisom
158	ERLOTINIB – Retail pharmacy-Specialist – Special Authority see SA2115 2000 (amended restriction criteria – new criteria shown only)			
	Tab 100 mg.....	764.00	30	✓ Tarceva
	Tab 150 mg.....	1,146.00	30	✓ Tarceva
	<p>► SA2115 2000 Special Authority for Subsidy Renewal - (pandemic circumstances) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 The patient is clinically benefiting from treatment and continued treatment remains appropriate; and 2 Erlotinib to be discontinued at progression; and 3 The regular Special Authority renewal requirements cannot be met due to COVID-19 constraints on the health sector.</p>			
159	GEFITINIB – Retail pharmacy-Specialist – Special Authority see SA2116 2004 (amended restriction criteria – new criteria shown only)			
	Tab 250 mg.....	1,700.00	30	✓ Iressa
	<p>► SA2116 2004 Special Authority for Subsidy Renewal - (pandemic circumstances) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 The patient is clinically benefiting from treatment and continued treatment remains; and 2 Gefitinib to be discontinued at progression; and 3 The regular Special Authority renewal requirements cannot be met due to COVID-19 constraints on the health sector.</p>			

Check your Schedule for full details Schedule page ref	Subsidy (Mnfr's price) \$	Per	Brand or Generic Mnfr ✓ fully subsidised
---	---------------------------------	-----	--

Changes to Restrictions – effective 1 April 2022 (continued)

163	SUNITINIB – Special Authority see SA2117 2002 – Retail pharmacy (amended restriction criteria – new criteria shown only)			
	Cap 12.5 mg	208.38	28	✓ Sunitinib Pfizer
		2,315.38		✓ Sutent
	Cap 25 mg	416.77	28	✓ Sunitinib Pfizer
		4,630.77		✓ Sutent
	Cap 50 mg	694.62	28	✓ Sunitinib Pfizer
		9,261.54		✓ Sutent

► **SA2117 2002** Special Authority for Subsidy

Renewal - (GIST pandemic circumstances) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 The patient has unresectable or metastatic malignant gastrointestinal stromal tumour (GIST); and
- 2 The patient is clinically benefiting from treatment and continued treatment remains appropriate; and
- 3 Sunitinib is to be discontinued at progression; and
- 4 The regular Special Authority renewal requirements cannot be met due to COVID-19 constraints on the health sector.

164	ABIRATERONE ACETATE – Retail pharmacy-Specialist – Special Authority see SA2118 2003 (amended restriction criteria – new criteria shown only)			
-----	--	--	--	--

Wastage claimable

Tab 250 mg.....	4,276.19	120	✓ Zytiga
-----------------	----------	-----	----------

► **SA2118 2003** Special Authority for Subsidy

Renewal - (pandemic circumstances) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 The patient is clinically benefiting from treatment and continued treatment remains appropriate; and
- 2 Abiraterone acetate to be discontinued at progression; and
- 3 No initiation of taxane chemotherapy with abiraterone; and
- 4 The regular Special Authority renewal requirements cannot be met due to COVID-19 constraints on the health sector.

166	OCTREOTIDE LONG-ACTING – Special Authority see SA2119 2072 – Retail pharmacy (amended restriction criteria – new criteria shown only)			
-----	--	--	--	--

Inj depot 10 mg prefilled syringe	439.97	1	✓ Octreotide Depot Teva
---	--------	---	-------------------------

Inj depot 20 mg prefilled syringe	647.03	1	✓ Octreotide Depot Teva
---	--------	---	-------------------------

Inj depot 30 mg prefilled syringe	718.55	1	✓ Octreotide Depot Teva
---	--------	---	-------------------------

► **SA2119 2072** Special Authority for Subsidy

Renewal - (Acromegaly - pandemic circumstances) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has acromegaly; and
- 2 The patient is clinically benefiting from treatment and continued treatment remains appropriate; and
- 3 The regular Special Authority renewal requirements cannot be met due to COVID-19 constraints on the health sector.

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist

* Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details
Schedule page ref

Subsidy
(Mnfr's price)
\$ Per

Brand or
Generic Mnfr
✓ fully subsidised

Changes to Restrictions – effective 1 April 2022 (continued)

201	RITUXIMAB (RIXIMYO) – PCT only – Specialist – Special Authority see SA2114 2003 (amended restriction criteria – new criteria shown only)			
	Inj 100 mg per 10 ml vial	275.33	2	✓ Riximyo
	Inj 500 mg per 50 ml vial	688.20	1	✓ Riximyo
	Inj 1 mg for ECP	1.38	1 mg	✓ Baxter (Riximyo)

►► **SA2114 2003** Special Authority for Subsidy

Initial application — (pemphigus*) only from a dermatologist or relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

1 All of the following:

- 1.1 Patient has severe rapidly progressive pemphigus; and
- 1.2 Is used in combination with systemic corticosteroids (20 mg/day); and
- 1.3 Any of the following:
 - 1.3.1 Skin involvement is at least 5% body surface area; or
 - 1.3.2 Significant mucosal involvement (10 or more mucosal erosions) or diffuse gingivitis or confluent large erosions; or
 - 1.3.3 Involvement of two or more mucosal sites; or

2 Both:

- 2.1 Patient has pemphigus; and
- 2.2 Patient has not experienced adequate clinical benefit from systemic corticosteroids (20 mg/day) in combination with a steroid sparing agent, unless contraindicated.

Note: Indications marked with * are unapproved indications.

Renewal — (pemphigus*) only from a dermatologist or relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Patient has experienced adequate clinical benefit from rituximab treatment, with improvement in symptoms and healing of skin ulceration and reduction in corticosteroid requirement; and
- 2 Patient has not received rituximab in the previous 6 months.

Note: Indications marked with * are unapproved indications.

Changes to Restrictions – effective 1 April 2022 (continued)

220 NIVOLUMAB – PCT only – Specialist – Special Authority see **SA2120 2006** (amended restriction criteria – new criteria shown only)

Inj 10 mg per ml, 4 ml vial	1,051.98	1	✓ Opdivo
Inj 10 mg per ml, 10 ml vial	2,629.96	1	✓ Opdivo
Inj 1 mg for ECP	27.62	1 mg	✓ Baxter

► **SA2120 2006** Special Authority for Subsidy

Renewal — (unresectable or metastatic melanoma) only from a medical oncologist or medical practitioner on the recommendation of a medical oncologist. Approvals valid for 4 months for applications meeting the following criteria:

Either:

1 All of the following:

1.1 Any of the following:

1.1.1 Patient's disease has had a complete response to treatment according to RECIST criteria (see Note); or

1.1.2 Patient's disease has had a partial response to treatment according to RECIST criteria (see Note); or

1.1.3 Patient has stable disease according to RECIST criteria (see Note); and

1.2 Either:

~~1.2.1 Response to treatment in target lesions has been determined by radiologic assessment (CT or MRI scan) following the most recent treatment period; or~~

~~1.2.2 Both:~~

~~1.2.2.1 Patient has measurable disease as defined by RECIST version 1.1; and~~

~~1.2.2.2 1.2 Patient's disease has not progressed clinically and disease response to treatment has been clearly documented in patient notes; and~~

1.3 No evidence of progressive disease according to RECIST criteria (see Note); and

1.4 The treatment remains clinically appropriate and the patient is benefitting from the treatment; or

2 All of the following:

2.1 Patient has previously discontinued treatment with nivolumab for reasons other than severe toxicity or disease progression; and

2.2 Patient has signs of disease progression; and

2.3 Disease has not progressed during previous treatment with nivolumab.

Check your Schedule for full details
Schedule page ref

Subsidy
(Mnfr's price)
\$ Per

Brand or
Generic Mnfr
✓ fully subsidised

Changes to Restrictions – effective 1 April 2022 (continued)

220 PEMBROLIZUMAB – PCT only – Specialist – Special Authority see **SA2121 2007** (amended restriction criteria – affected criteria shown only)

Inj 25 mg per ml, 4 ml vial	4,680.00	1	✓ Keytruda
Inj 1 mg for ECP	49.14	1 mg	✓ Baxter

► **SA2121 2007** Special Authority for Subsidy

Renewal — (unresectable or metastatic melanoma) only from a medical oncologist or medical practitioner on the recommendation of a medical oncologist. Approvals valid for 4 months for applications meeting the following criteria:

Either:

1 All of the following:

1.1 Any of the following:

- 1.1.1 Patient's disease has had a complete response to treatment according to RECIST criteria (see Note); or
- 1.1.2 Patient's disease has had a partial response to treatment according to RECIST criteria (see Note); or
- 1.1.3 Patient has stable disease according to RECIST criteria (see Note); and

1.2 Either:

1.2.1 ~~Response to treatment in target lesions has been determined by radiologic assessment (CT or MRI scan) following the most recent treatment period; or~~

1.2.2 ~~Both:~~

~~1.2.2.1 Patient has measurable disease as defined by RECIST version 1.1; and~~

~~1.2.2.2 Patient's disease has not progressed clinically and disease response to treatment has been clearly documented in patient notes; and~~

1.3 No evidence of progressive disease according to RECIST criteria (see Note); and

1.4 The treatment remains clinically appropriate and the patient is benefitting from the treatment; or

2 All of the following:

- 2.1 Patient has previously discontinued treatment with pembrolizumab for reasons other than severe toxicity or disease progression; and
- 2.2 Patient has signs of disease progression; and
- 2.3 Disease has not progressed during previous treatment with pembrolizumab.

Check your Schedule for full details
Schedule page ref

Subsidy
(Mnfr's price)
\$ Per

Brand or
Generic Mnfr
✓ fully subsidised

Changes to Subsidy and Manufacturer's Price

Effective 1 April 2022

53	SPIRONOLACTONE (↓ subsidy) * Tab 25 mg..... * Tab 100 mg.....	3.68 10.65	100 100	✓ Spiractin ✓ Spiractin
65	AQUEOUS CREAM (↓ subsidy) * Crm.....	1.73	500 g	✓ Boucher
83	CARBIMAZOLE (↓ subsidy) * Tab 5 mg.....	7.56	100	✓ Neo-Mercazole
116	COLCHICINE (↓ subsidy) * Tab 500 mcg.....	6.00	100	✓ Colgout
146	CARMUSTINE – PCT only – Specialist (↓ subsidy) Inj 100 mg vial..... Inj 100 mg for ECP	710.00 710.00	1 100 mg OP	✓ BiCNU ✓ Baxter
227	PROMETHAZINE HYDROCHLORIDE (↓ subsidy) * Tab 10 mg..... * Tab 25 mg.....	1.39 1.58	50 50	✓ Allersoothe ✓ Allersoothe
228	SALMETEROL (↑ subsidy) Aerosol inhaler CFC-free, 25 mcg per dose Powder for inhalation, 50 mcg per dose, breath activated	26.25 26.25	120 dose OP 60 dose OP	✓ Serevent ✓ Serevent Accuhaler
229	SALBUTAMOL (↑ manufacturer's price) Aerosol inhaler, 100 mcg per dose CFC free – Up to 1000 dose available on a PSO	3.80 (6.20)	200 dose OP	Ventolin

▲ Three months supply may be dispensed at one time if endorsed
“certified exemption” by the prescriber or pharmacist

* Three months or six months, as
applicable, dispensed all-at-once

Check your Schedule for full details
Schedule page ref

Subsidy
(Mnfr's price)
\$ Per

Brand or
Generic Mnfr
✓ fully subsidised

Delisted Items

Effective 1 April 2022

65	AQUEOUS CREAM * Crm.....	1.92	500 g	✓ Basic AquaCream ✓ Boucher ✓ Medco
	Note – Boucher crm, 500 g delist delayed to 1 August 2022.			
78	CINACALCET – Special Authority see SA1618 – Retail pharmacy Tab 30 mg – Wastage claimable.....	210.30	28	✓ Sensipar
81	OESTRADIOL VALERATE * Tab 2 mg.....	12.36	84	✓ Progynova
	Note – this delist is for Pharmacode 2450461.			
91	ERYTHROMYCIN STEARATE Tab 250 mg – Up to 30 tab available on a PSO.....	14.95 (22.29)	100	ERA
118	ENTACAPONE ▲ Tab 200 mg.....	22.00	100	✓ Entapone
119	SELEGILINE HYDROCHLORIDE – Subsidy by endorsement Subsidy by endorsement – Subsidised for patients who were taking selegiline hydrochloride prior to 1 August 2021 and the prescription is endorsed accordingly. Pharmacists may annotate the prescription as endorsed where there exists a record of prior dispensing of selegiline hydrochloride. * Tab 5 mg.....	22.00	100	✓ Apo-Selegiline S29 S29
131	CLOZAPINE – Hospital pharmacy [HP4] Safety medicine; prescriber may determine dispensing frequency Suspension 50 mg per ml.....	17.33	100 ml	✓ Clopine
134	OXAZEPAM – Safety medicine; prescriber may determine dispensing frequency Tab 10 mg..... Tab 15 mg.....	6.17 8.53	100 100	✓ Ox-Pam ✓ Ox-Pam
137	MELATONIN – Special Authority see SA1666 – Retail pharmacy Tab modified-release 2 mg – No more than 5 tab per day.....	28.22	30	✓ Circadin
238	CYCLOPENTOLATE HYDROCHLORIDE * Eye drops 1%, single dose (preservative free) – Only on a Prescription.....	52.86	20 dose	✓ Minims Cyclopentolate
240	PHARMACY SERVICES May only be claimed once per patient. * Brand switch fee.....	4.50	1 fee	✓ BSF Febuxostat multichem
265	HIGH FAT LOW CARBOHYDRATE FORMULA – Special Authority see SA1197 – Retail pharmacy Powder (unflavoured)..... Note – this delist is for Pharmacode 2431637.	35.50	300 g OP	✓ Ketocal 3:1

Check your Schedule for full details
Schedule page ref

Subsidy
(Mnfr's price)
\$ Per

Brand or
Generic Mnfr
✓ fully subsidised

Items to be Delisted

Effective 1 July 2022

240	PHARMACY SERVICES May only be claimed once per patient. * Brand switch fee.....	4.50	1 fee	✓ BSF Vigisom ✓ BSF Cinacalcet Devatis ✓ BSF Comtan
-----	---	------	-------	--

Note – the Pharmacode for BSF Vigisom is 2634112. The Pharmacode for BSF Cinacalcet Devatis is 2634120. The Pharmacode for BSF Comtan is 2634139.

Effective 1 August 2022

65	AQUEOUS CREAM * Crm.....	1.73	500 g	✓ Boucher
----	-----------------------------	------	-------	------------------

Note – this delist is delayed from 1 April 2022 to 1 August 2022.

131	AMISULPRIDE – Safety medicine; prescriber may determine dispensing frequency Tab 100 mg.....	17.16	100	✓ Amisulpride Mylan \$29
-----	---	-------	-----	--

Effective 1 September 2022

58	OIL IN WATER EMULSION * Crm.....	2.19	500 g	✓ O/W Fatty Emulsion Cream
----	-------------------------------------	------	-------	---

146	CARMUSTINE – PCT only – Specialist Inj 100 mg vial.....	1,387.00	1	✓ Bicnu Heritage \$29
-----	--	----------	---	-------------------------------------

Effective 1 October 2022

91	ERYTHROMYCIN ETHYL SUCCINATE Grans for oral liq 200 mg per 5 ml	5.00	100 ml	✓ E-Mycin
----	--	------	--------	------------------

a) Up to 300 ml available on a PSO
b) Up to 2 x the maximum PSO quantity for RFPP
c) Wastage claimable

Note – this delist is for Pharmacode 243078.

Effective 1 November 2022

91	ERYTHROMYCIN ETHYL SUCCINATE Grans for oral liq 400 mg per 5 ml	6.77	100 ml	✓ E-Mycin
----	--	------	--------	------------------

a) Up to 200 ml available on a PSO
b) Wastage claimable

Note – this delist is for Pharmacode 243086.

131	AMISULPRIDE – Safety medicine; prescriber may determine dispensing frequency Tab 100 mg.....	5.15	30	✓ Sulprix
-----	---	------	----	------------------

Note – this delist is for Pharmacode 2500132.

▲ Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber or pharmacist

* Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details
Schedule page ref

Subsidy
(Mnfr's price)
\$ Per

Brand or
Generic Mnfr
✓ fully subsidised

Items to be Delisted – effective 1 November 2022 (continued)

261	AMINO ACID FORMULA – Special Authority see SA2092 – Hospital pharmacy [HP3] Powder.....	43.60	400 g OP	✓ Alfamino ✓ Alfamino Junior
Note – these delists are for Pharmacodes 2608227 and 2510537 respectively.				

Effective 1 January 2023

168	AZATHIOPRINE * Inj 50 mg vial.....	199.00	1	✓ Imuran
-----	---------------------------------------	--------	---	----------

Effective 1 June 2023

24	PANCREATIC ENZYME Cap pancreatin (175 mg (25,000 U lipase, 22,500 U amylase, 1,250 U protease)).....	94.40	100	✓ Panzytrat
----	--	-------	-----	-------------

Index

Pharmaceuticals and brands

A

Abiraterone acetate	25
Aclasta	23
Alfamino	22, 32
Alfamino Junior	22, 32
Allersoothe	29
Amino acid formula	22, 32
Amisulpride	31
Amisulpride Mylan	31
Apo-Selegiline S29	30
Aqueous cream	29, 30, 31
Azathioprine	32

B

Basic AquaCream	30
BiCNU	29
Bicnu Heritage	31
BSF Cinacalcet Devatis	22, 31
BSF Comtan	22, 31
BSF Febuxostat multichem	30
BSF Vigisom	22, 31

C

Carbimazole	29
Carmustine	29, 31
Cinacalcet	23, 30
Cinacalcet Devatis	23
Circadin	30
Clopine	30
Clozapine	30
Colchicine	29
Colgout	29
Comtan	24
Cyclopentolate hydrochloride	30

E

E-Mycin	31
Entacapone	24, 30
Entapone	30
ERA	30
Erlotinib	24
Erythromycin ethyl succinate	31
Erythromycin stearate	30

F

Fatty Cream AFT	22
Febuxostat	24
Febuxostat multichem	24

G

Gefitinib	24
-----------------	----

H

High fat low carbohydrate formula	30
---	----

I

Imuran	32
Iressa	24

K

Ketocal 3:1	30
Keytruda	28

L

Lyrica	24
--------------	----

M

Melatonin	24, 30
Minims Cyclopentolate	30

N

Neo-Mercazole	29
Nivolumab	27

O

Octreotide Depot Teva	25
Octreotide long-acting	25
Oestradiol valerate	30
Oil in water emulsion	22, 31
Opdivo	27
O/W Fatty Emulsion Cream	31
Oxazepam	30
Ox-Pam	30

P

Pancreatic enzyme	32
Panzytrat	32
Pembrolizumab	28
Pharmacy services	22, 30, 31
Pregabalin	24
Pregabalin Pfizer	24
Progynova	30
Promethazine hydrochloride	29

R

Rituximab (Riximyo)	26
Riximyo	26

S

Salbutamol	29
Salmeterol	29
Selegiline hydrochloride	30
Sensipar	30
Serevent	29
Serevent Accuhaler	29
Spiractin	29
Spironolactone	29
Sulprix	31
Sunitinib	25
Sunitinib Pfizer	25
Sutent	25

Index

Pharmaceuticals and brands

T

Tarceva..... 24

V

Ventolin 29

Vigisom 24

Z

Zoledronic acid 23

Zoledronic acid Mylan 23

Zytiga..... 25

New Zealand
Permit No. 478



Pharmaceutical Management Agency

Level 9, 40 Mercer Street, PO Box 10254, Wellington 6143, New Zealand

Phone: 64 4 460 4990 - Fax: 64 4 460 4995 - www.pharmac.govt.nz

Email: enquiry@pharmac.govt.nz

ISSN 1172-9376 (Print)

ISSN 1179-3686 (Online)

Te Kāwanatanga o [Aotearoa](#) [New Zealand](#) Government

While care has been taken in compiling this Update, Pharmaceutical Management Agency takes no responsibility for any errors or omissions and shall not be liable to any person for any damages or loss arising out of reliance by that person for any purpose on any of the contents of this Update. Errors and omissions brought to the attention of Pharmaceutical Management Agency will be corrected if necessary by an erratum or otherwise in the next edition of the update.

If Undelivered, Return To: PO Box 10254, Wellington 6143, New Zealand